1. Home
  2. ENSC vs ATXG Comparison

ENSC vs ATXG Comparison

Compare ENSC & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • ATXG
  • Stock Information
  • Founded
  • ENSC 2003
  • ATXG 2014
  • Country
  • ENSC United States
  • ATXG China
  • Employees
  • ENSC N/A
  • ATXG N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • ATXG Professional Services
  • Sector
  • ENSC Health Care
  • ATXG Consumer Discretionary
  • Exchange
  • ENSC Nasdaq
  • ATXG Nasdaq
  • Market Cap
  • ENSC 5.5M
  • ATXG 5.4M
  • IPO Year
  • ENSC N/A
  • ATXG N/A
  • Fundamental
  • Price
  • ENSC $2.64
  • ATXG $0.77
  • Analyst Decision
  • ENSC
  • ATXG
  • Analyst Count
  • ENSC 0
  • ATXG 0
  • Target Price
  • ENSC N/A
  • ATXG N/A
  • AVG Volume (30 Days)
  • ENSC 24.9K
  • ATXG 5.8K
  • Earning Date
  • ENSC 05-12-2025
  • ATXG 02-14-2025
  • Dividend Yield
  • ENSC N/A
  • ATXG N/A
  • EPS Growth
  • ENSC N/A
  • ATXG N/A
  • EPS
  • ENSC N/A
  • ATXG N/A
  • Revenue
  • ENSC $5,210,031.00
  • ATXG $4,549,310.00
  • Revenue This Year
  • ENSC N/A
  • ATXG N/A
  • Revenue Next Year
  • ENSC N/A
  • ATXG N/A
  • P/E Ratio
  • ENSC N/A
  • ATXG N/A
  • Revenue Growth
  • ENSC 133.58
  • ATXG N/A
  • 52 Week Low
  • ENSC $2.12
  • ATXG $0.49
  • 52 Week High
  • ENSC $14.67
  • ATXG $1.18
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 23.45
  • ATXG 41.97
  • Support Level
  • ENSC $3.30
  • ATXG $0.81
  • Resistance Level
  • ENSC $3.58
  • ATXG $0.89
  • Average True Range (ATR)
  • ENSC 0.32
  • ATXG 0.06
  • MACD
  • ENSC -0.05
  • ATXG -0.01
  • Stochastic Oscillator
  • ENSC 22.21
  • ATXG 11.21

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Share on Social Networks: